Clinical Trial Detail

NCT ID NCT03549338
Title Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Symphogen A/S
Indications

colorectal cancer

Therapies

Modotuximab

Futuximab

SYM004

Age Groups: adult senior

No variant requirements are available.